Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.

In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.

Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7^th Obesity & NASH Drug Development Summit is your exclusive industry meeting to:

• better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
• explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
• ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action

Join 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH.